The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.The trial compared lenvatinib to placebo and demonstrated a statistically significant improvement in PFS, which Eisai plans to submit for marketing authorization in the United States, Japan, and Europe, the company said in a statement. In a phase II study of Lenvatinib, a selective inhibitor of VEGFR 1-3, FGFR 1-4,... Continue reading
ITOG is pleased to report that four ITOG members will be moderators and/or panelists in the 2nd Annual New York Masters Course in Endocrine Surgery, December 6-7 at Icahn School of Medicine at Mount Sinai, New York, New York. The course will be an intensive review of key endocrine surgery topics, with special focus on current trends and techniques. This will include viewing live demonstrations of minimally invasive surgery for thyroidectomy and parathyroidectomy. Online registration is available at: http://www.mastersinendocrine.com Friday,... Continue reading
Jean G. Vicks passed away on April 5, 2013 after her fourteen year battle with medullary thyroid cancer (MTC). She was 49. The diagnosis of MTC in 1999 resulted in seven surgeries, two clinical trials and three additional chemotherapy regimens in her desire to be well. Jean was honored as the inspiration for ITOG at the ITOG Annual Meeting at the Mayo Clinic in April. Jean’s grace, selflessness and enthusiasm in the face of overwhelming challenges are an inspiration to all who knew her. When Jean was diagnosed, she made a goal to live long enough to see her children begin college. Jean... Continue reading
TA Associates Realty is one of the leading investors in commercial real estate in the United States. Michael Ruane, a founding member of TA Associates Realty, created an event to provide a valuable business gathering, golf at exceptional courses and raise funds to donate to worthy charities selected by the TA Associates team. ITOG was selected as the 2013 Charitable Beneficiary for the event held on July 29th. The day began with an informative business forum including a round table of leading executives from across the country. After lunch, participants played the historic Blue Hill... Continue reading
October 9, 2013 The 16th annual International Thyroid Cancer Survivors’ www.ThyCa.org conference took place from September 27-29, 2013 in Philadelphia. A record breaking 550 attendees came to the meeting. Through this conference, ThyCa is able to bring together the latest research, advances in treatment, follow-up and coping skills for the well-being of thyroid cancer survivors and their caregivers. Dr. Steven Sherman, Dr. Lori Wirth and Dwight Vicks, ITOG board members, led two sessions in the conference. The sessions, Learn about the International... Continue reading
(ASCO, June 2, 2013) A large phase III clinical trial reported that sorafenib improves progression free survival for patients with radioactive iodine refractory, differentiated thyroid cancer. June 2, 2013 marks a major milestone in thyroid cancer, as ITOG member Marcia Brose, MD, PhD, Assistant Professor of Medicine, Hematology/Oncology and of Otolaryngology and Head and Neck Surgery in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania in Philadelphia, presented the results from the DECISION trial, the first randomized, phase III clinical trial of... Continue reading
For advanced non-resectable MTC (medullary thyroid cancer), there are now two FDA-approved drugs, vandetanib (Caprelsa) and cabozantinib (Cometriq). At the 2013 American Society of Clinical Oncology meeting in Chicago, ITOG investigators working with Exelixis, Inc. reported a major study of the impact of different gene mutations in MTC tumors on responses to cabozantinib. Using a large data set from the Phase III clinical trial that led to the approval of the drug earlier this year, the investigators retrospectively studied several key DNA mutations identified in previous studies of MTC... Continue reading
ITOG held its 2013 Annual Meeting in Rochester, Minnesota at Mayo Medical Center on April 28-30th. The meeting was hosted by Drs. Keith Bible and Robert Smallridge. Highlights from the meeting included scientific sessions on Molecular Therapeutic Approaches to Thyroid Cancer. Dr. Steve Russell outlined his program for developing oncolytic viruses and described the efforts to bring these to the clinic. ITOG members had an orientation and overview of ACCRU, which included tours of Mayo/ACCRU research laboratories and specimen handling/archiving facilities. Scientific sessions included... Continue reading
ITOG is poised to open it’s first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGR inhibitor benefit from treatment with Cabozantinib.NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on first-line therapy with a VEGFR antagonist. ITOG’s first... Continue reading
December, 2012. The International Thyroid Oncology Group (ITOG) has completed a major period of membership expansion, doubling its membership. ITOG members hail from 29 leading academic medical institutions on three continents. ITOG counts numerous leading European thyroid specialists among its membership. ITOG members are drawn from every aspect of clinical, pathological, and scientific disciplines to assemble a “dream-team” of specialists for thyroid cancer. ITOG members are united by the belief that working together is the only way to catalyze a cure for thyroid cancer.
December, 2012: ITOG records its best year to date in fund raising. Since its inception in 2007, donations to ITOG have primarily come from individuals who have been personally affected by thyroid cancer. The Larkin Family, pictured, have raised over $80,000 for ITOG through its annual Kel Klassic golf tournament. “Team Jean” reached $100,000 in donations this year. Please contact Dwight Vicks, ITOG Treasurer, if you would like to make a donation and help ITOG catalyze a cure for thyroid cancer. ITOG is a driving force leading advancements in... Continue reading
April, 2012: Dr. Steven I. Sherman of MD Anderson Cancer Center was re-elected as ITOG Chairman after an extraordinary year of leadership. Dr. Sherman’s first year as Chairman was notable for leading a partnership agreement with ACCRU, and activating the Clinical Protocol and Correlative Science Committees. Dr. Sherman will be joined on the Executive Committee by Dr. Lori Wirth, who was elected as Secretary. Dr. Wirth is the Director, Head & Neck Oncology at Massachusetts General Hospital. Dr. Wirth also serves as Chair of the ITOG Clinical Protocols Committee, the committee charged... Continue reading
April 2012: Drs. Manisha Shah and Matt Ringel hosted the 2012 Annual Meeting at The Ohio State University College of Medicine on April 29-30th. This annual event has become a critical event for ITOG members to share the latest clinical and scientific results and to prioritize the direction of future clinical and research studies. ITOG is characterized by a strong commitment to collaboration in order to advance our mission. The 2013 ITOG Annual Meeting will be hosted by ITOG members: Drs. Bible, Bernet, Menefee and Smallridge of the Mayo Clinic in Rochester, Minnesota.
March, 2012: The ITOG Board of Directors endorsed a partnership with Academic and Community Cancer Research United (ACCRU) an affiliate of Mayo Clinic, Rochester, to conduct clinical trials. ACCRU was selected after an extensive search to identify a partner to provide robust infrastructure necessary for thyroid cancer clinical trials. ITOG’s focus on clinical trials is an effort to build on recent success and bring new targeted therapies to thyroid cancer patients with advanced disease. The timing of this agreement is ideal. ITOG has received approval from the National Cancer Institute (... Continue reading